Paper39436624
A case of successful conversion surgery for unresectable gallbladder cancer treated with durvalumab in combination with gemcitabine plus cisplatin.
Araki T and 9 others. Clin J Gastroenterol, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. A case of successful conversion surgery for unresectable gallbladder cancer treated with durvalumab in combination with gemcitabine plus cisplatin. Papers, record 39436624. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39436624
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A case of successful conversion surgery for unresectable gallbladder cancer treated with durvalumab in combination with gemcitabine plus cisplatin.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gallbladder Neoplasms | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Antibodies, Monoclonal | Major topic |
| Humans | |
| Female | |
| Gemcitabine | |
| Deoxycytidine | |
| Cisplatin | |
| Aged | |
| Lymph Node Excision |
Source PubMed
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35039070 | Locally advanced gallbladder cancer treated with effective chemotherapy and subsequent curative resection: a case report. | J Med Case Rep | 2022 | https://conductscience.org/library/papers/35039070 | PubMed |
| 2 | 33860135 | Essential updates 2019/2020: Surgical treatment of gallbladder cancer. | Ann Gastroenterol Surg | 2021 | https://conductscience.org/library/papers/33860135 | PubMed |
| 3 | 27025903 | Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT). | Jpn J Clin Oncol | 2016 | https://conductscience.org/library/papers/27025903 | PubMed |
| 4 | 37076889 | Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. | Diagn Pathol | 2023 | https://conductscience.org/library/papers/37076889 | PubMed |
| 5 | 38319896 | Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. | NEJM Evid | 2022 | https://conductscience.org/library/papers/38319896 | PubMed |
| 6 | 36242892 | Curative surgical resection for initially unresectable metastatic gallbladder cancer following neoadjuvant chemotherapy: Case report and review of literature. | Int J Surg Case Rep | 2022 | https://conductscience.org/library/papers/36242892 | PubMed |
| 7 | 34402435 | Conversion surgery for initially unresectable extrahepatic biliary tract cancer. | Ann Hepatobiliary Pancreat Surg | 2021 | https://conductscience.org/library/papers/34402435 | PubMed |
| 8 | 37184729 | Induction chemotherapy and hepatic artery embolization followed by extended resection for locally advanced gallbladder cancer: a case report. | Surg Case Rep | 2023 | https://conductscience.org/library/papers/37184729 | PubMed |
| 9 | 35332404 | Conversion surgery following gemcitabine plus cisplatin therapy for initially unresectable gallbladder cancer with peritoneal carcinomatosis: a case report. | Surg Case Rep | 2022 | https://conductscience.org/library/papers/35332404 | PubMed |
| 10 | 21490453 | Gallbladder cancer involving the extrahepatic bile duct is worthy of resection. | Ann Surg | 2011 | https://conductscience.org/library/papers/21490453 | PubMed |
| 11 | 36575822 | Survival after extended resections for gallbladder cancer. | Ann Hepatobiliary Pancreat Surg | 2023 | https://conductscience.org/library/papers/36575822 | PubMed |
| 12 | 36052238 | Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy. | Front Oncol | 2022 | https://conductscience.org/library/papers/36052238 | PubMed |
| 13 | 31825009 | Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection. | Ann Hepatobiliary Pancreat Surg | 2019 | https://conductscience.org/library/papers/31825009 | PubMed |
| 14 | 38123314 | PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer. | BMJ Case Rep | 2023 | https://conductscience.org/library/papers/38123314 | PubMed |
| 15 | 35666061 | Impact of delay in adjuvant therapy for gallbladder adenocarcinoma. | J Hepatobiliary Pancreat Sci | 2023 | https://conductscience.org/library/papers/35666061 | PubMed |
| 16 | 35079922 | Pathological complete response achieved by gemcitabine plus cisplatin therapy for initially unresectable advanced gallbladder cancer: a case report. | Surg Case Rep | 2022 | https://conductscience.org/library/papers/35079922 | PubMed |
| 17 | 28497252 | Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable? | J Gastrointest Surg | 2017 | https://conductscience.org/library/papers/28497252 | PubMed |
| 18 | 27864927 | Indications for major hepatectomy and combined procedures for advanced gallbladder cancer. | Br J Surg | 2017 | https://conductscience.org/library/papers/27864927 | PubMed |
| 19 | 37369470 | Expression and Prognostic Significance of PD-L1 and NY-ESO1 in Gallbladder Carcinoma. | In Vivo | 2023 | https://conductscience.org/library/papers/37369470 | PubMed |
| 20 | 35900311 | Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). | J Hepatobiliary Pancreat Sci | 2023 | https://conductscience.org/library/papers/35900311 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42519320 | Case Report: Successful R0 resection following conversion immunochemotherapy in a patient with biliary tract cancer and multiple metastases discovered after laparoscopic gallstone surgery. | Front Immunol | 2026 | https://conductscience.org/library/papers/42519320 | PubMed |
| 42339344 | A Case of Unresectable Ampulla of Vater Carcinoma Successfully Treated with Conversion Surgery Following Sequential Systemic Chemotherapy Including Durvalumab. | Surg Case Rep | 2026 | https://conductscience.org/library/papers/42339344 | PubMed |
| 41929550 | A case of perihilar cholangiocarcinoma with peritoneal dissemination that achieved a pathological complete response using immune checkpoint inhibitors: A case report. | Int Cancer Conf J | 2026 | https://conductscience.org/library/papers/41929550 | PubMed |
| 41236594 | Durable response to chemotherapy enabling conversion surgery in stage IVB gallbladder cancer: a case successfully treated with durvalumab combined with gemcitabine plus cisplatin. | Clin J Gastroenterol | 2026 | https://conductscience.org/library/papers/41236594 | PubMed |
| 41080570 | Long-term survival after targeted therapy plus immunotherapy without chemotherapy in advanced gallbladder carcinoma: a case report and literature review. | Front Immunol | 2025 | https://conductscience.org/library/papers/41080570 | PubMed |
| 40242270 | Immunotherapy for primary squamous cell carcinoma of the liver: A case report. | Oncol Lett | 2025 | https://conductscience.org/library/papers/40242270 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39436624
GET https://conductscience.org/api/papers/v1/39436624/references?page=2